Robin Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robin Chung has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Arjun Kumar Ghosh
Cardio-Oncology Service, University College London Hospital, University College London Hospitals NHS Foundation Trust, London, UK
1 shared publication - Avirup Guha
Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH 43210, USA
1 shared publication - Daniel Addison
Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, OH 43210, USA
1 shared publication - Daniel H. Chen
University College Hospital University College London Hospitals NHS Foundation Trust London UK
1 shared publication - John Malcolm Walker
Hatter Cardiovascular Institute, University College London, London, United Kingdom
1 shared publication - Roohi Ismail-Khan
Moffitt Cancer Center, Tampa, FL
1 shared publication
Latest Publications
- Open Access
- 18 October 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3346
Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology
Cardiotoxicity is the umbrella term for cardiovascular side effects of cancer therapies. The most widely recognized phenotype is left ventricular dysfunction, but cardiotoxicity can manifest as arrhythmogenic, vascular, myocarditic and hypertensive toxicities. Hypertension has long been regarded as one of the most prevalent and modifiable cardiovascular risk factors in the general population, but its relevance during the cancer treatment journey may be underestimated. Hypertensive cardiotoxicity occurs de novo in a substantial proportion of treated cancer patients. The pathology is incompletely characterized—natriuresis and renin angiotensin system interactions play a role particularly in conventional treatments, but in novel therapies endothelial dysfunction and the interaction between the cancer and cardiac kinome are implicated. There exists a treatment paradox in that a significant hypertensive response not only mandates anti-hypertensive treatment, but in fact, in certain cancer treatment scenarios, hypertension is a predictor of cancer treatment efficacy and response. In this comprehensive review of over 80,000 patients, we explored the epidemiology, incidence, and mechanistic pathophysiology of hypertensive cardiotoxicity in adjunct, conventional chemotherapy, and novel cancer treatments. Conventional chemotherapy, adjunct treatments, and novel targeted therapies collectively caused new onset hypertension in 33–68% of treated patients. The incidence of hypertensive cardiotoxicity across twenty common novel therapies for any grade hypertension ranged from 4% (imatinib) to 68% (lenvatinib), and high grade 3 or 4 hypertension in <1% (imatinib) to 42% (lenvatinib). The weighted average effect was all-grade hypertension in 24% and grade 3 or 4 hypertension in 8%.
- 18 October 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10) , 3346
Open AccessHypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology
Cardiotoxicity is the umbrella term for cardiovascular side effects of cancer therapies. The most widely recognized phenotype is left ventricular dysfunction, but cardiotoxicity can manifest as arrhythmogenic, vascular, myocarditic and hypertensive toxicities. Hypertension has long been regarded as one of the most prevalent and modifiable cardiovascular risk factors in the general population, but its relevance during the cancer treatment journey may be underestimated. Hypertensive cardiotoxicity occurs de novo in a substantial proportion of treated cancer patients. The pathology is incompletely characterized—natriuresis and renin angiotensin system interactions play a role particularly in conventional treatments, but in novel therapies endothelial dysfunction and the interaction between the cancer and cardiac kinome are implicated. There exists a treatment paradox in that a significant hypertensive response not only mandates anti-hypertensive treatment, but in fact, in certain cancer treatment scenarios, hypertension is a predictor of cancer treatment efficacy and response. In this comprehensive review of over 80,000 patients, we explored the epidemiology, incidence, and mechanistic pathophysiology of hypertensive cardiotoxicity in adjunct, conventional chemotherapy, and novel cancer treatments. Conventional chemotherapy, adjunct treatments, and novel targeted therapies collectively caused new onset hypertension in 33–68% of treated patients. The incidence of hypertensive cardiotoxicity across twenty common novel therapies for any grade hypertension ranged from 4% (imatinib) to 68% (lenvatinib), and high grade 3 or 4 hypertension in <1% (imatinib) to 42% (lenvatinib). The weighted average effect was all-grade hypertension in 24% and grade 3 or 4 hypertension in 8%.
- Open Access
- 7 April 2015
- Published by International Cardiovascular Forum Journal in International Cardiovascular Forum Journal
- Vol. 1 (2) , 62-67
Transcatheter Aortic Valve Implantation (TAVI) for Aortic Stenosis
Aortic stenosis remains the commonest form of valve disease in modern cardiology. With fifty years’ experience, surgical valve replacement remains the gold standard treatment for survival benefit, durability and symptomatic relief. Percutaneous transcatheter aortic valve replacement has recently gained a credible momentum for inoperable and very high risk patients with severe aortic stenosis. Early and medium term results have demonstrated a proven survival benefit over conservative management, with documented complication rates for stroke, vascular complications and pacemaker implantation. The evidence base for cost effectiveness and long-term results are eagerly anticipated.
- 7 April 2015
- Published by International Cardiovascular Forum Journal in International Cardiovascular Forum Journal
- Vol. 1 (2) , 62-67
Open AccessTranscatheter Aortic Valve Implantation (TAVI) for Aortic Stenosis
Aortic stenosis remains the commonest form of valve disease in modern cardiology. With fifty years’ experience, surgical valve replacement remains the gold standard treatment for survival benefit, durability and symptomatic relief. Percutaneous transcatheter aortic valve replacement has recently gained a credible momentum for inoperable and very high risk patients with severe aortic stenosis. Early and medium term results have demonstrated a proven survival benefit over conservative management, with documented complication rates for stroke, vascular complications and pacemaker implantation. The evidence base for cost effectiveness and long-term results are eagerly anticipated.